In this case, we report a novel <i>LDLR-ROS1</i> fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC. This evidence concerns the gene ROS1 and lung adenocarcinoma.